Genedrive Plc GDR

LSE · United Kingdom · Health Technology

GBp 1.200.00 (0.00%)

Market closed· Oct 1, 2026, 2:05 PM UTC· GBp · Data may be delayed

Company news

Yahoo FinanceSep 09, 2026

genedrive CEO: NHS adoption and global expansion drive point-of-care testing push

genedrive PLC (AIM:GDR) CEO Dr Gino Miele spoke with Proactive's Stephen Gunnion about the diagnostic company's progress in rapid point-of-care genetic testing, growing NHS adoption and international expansion plans. Miele explained that Manchester-based genedrive has developed two CE-IVD-approved, NICE-recommended tests to help clinicians make safer prescribing decisions in emergency and acute care. The MT-RNR1 test identifies newborns at risk of irreversible hearing loss from aminoglycoside antibiotics, while the CYP2C19 test identifies stroke patients unlikely to respond well to the antipla

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.